US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment EP News Bureau Aug 22, 2023 The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk…
US FDA grants Breakthrough Therapy Designation for Takeda’s Pevonedistat EP News Bureau Jul 31, 2020 The investigational drug is for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)
